Taspoglutide: Molecular Structure

Molecular Structure and Properties#

Taspoglutide is a 30-amino-acid synthetic peptide analog of human GLP-1(7-36 amide), developed by Ipsen and licensed to Roche. With a molecular weight of approximately 3,430.8 Da, molecular formula C153H225N37O49, and CAS number 275371-94-3, taspoglutide was designed to retain the full receptor potency of native GLP-1 while gaining enzymatic resistance through minimal sequence modifications.

Amino Acid Sequence#

The primary structure of taspoglutide is:

His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Aib-Arg-NH2

This sequence incorporates two key modifications from native GLP-1(7-36 amide):

• Position 8 (Aib): Replaces native alanine. The alpha-aminoisobutyric acid substitution provides steric resistance to dipeptidyl peptidase-4 (DPP-4), which normally cleaves GLP-1 between positions 8 and 9 with a half-life of approximately 2 minutes.
• Position 35 (Aib): Replaces native glycine at the C-terminal region. This second Aib substitution provides additional structural stability and may contribute to the helical conformation that optimizes receptor binding.
• C-terminal amidation: The arginine at position 30 is C-terminally amidated (-NH2), consistent with the native GLP-1(7-36 amide) form.

With only two amino acid substitutions from the native sequence, taspoglutide retained 93% sequence homology with human GLP-1(7-36 amide), the highest among GLP-1 analogs developed for clinical use.

Depot Formulation#

Unlike semaglutide (acylation for albumin binding) or albiglutide (albumin fusion), taspoglutide achieved once-weekly duration through a zinc-based slow-release depot formulation rather than molecular modifications for extended half-life:

• Zinc complexation: Taspoglutide was formulated with zinc chloride, forming a zinc-peptide complex that precipitated at the subcutaneous injection site
• Slow dissolution: The zinc complex slowly dissolved, releasing free peptide over approximately 7 days
• Depot mechanism: This approach is analogous to the zinc-protamine insulin formulations used for insulin NPH, applied to a GLP-1 peptide

This formulation strategy had both advantages and disadvantages. The advantage was that no additional molecular modifications beyond the Aib substitutions were needed, preserving the near-native GLP-1 structure. The disadvantage was the formation of a subcutaneous depot that contributed to injection-site reactions, local immune responses, and ultimately the immunogenicity that led to the drug's failure.

Pharmacokinetics#

Absorption: Taspoglutide was absorbed slowly from the zinc-based subcutaneous depot, with sustained plasma levels over the weekly dosing interval. The depot formulation controlled the rate of peptide release rather than albumin binding or PEGylation.

Distribution: Distribution was primarily in the vascular compartment, similar to other GLP-1 analogs.

Metabolism: Like native GLP-1, taspoglutide was metabolized through proteolytic degradation. The Aib substitutions protected against DPP-4 cleavage but did not prevent other endopeptidase activity.

Elimination: The effective half-life was approximately 7 days based on the depot formulation release rate, supporting once-weekly dosing.

Immunogenicity#

Taspoglutide's most critical molecular liability was its immunogenicity. Despite 93% homology with native GLP-1, the combination of the two Aib substitutions and the zinc-depot formulation triggered immune responses in approximately 49% of patients. Anti-taspoglutide antibodies contributed to allergic reactions, injection-site reactions, and potentially reduced efficacy over time. This immunogenicity was a key factor in the drug's discontinuation.

Structural Comparison with Related GLP-1 Analogs#

• vs. Semaglutide: Semaglutide uses a single Aib substitution at position 8 plus a C18 fatty diacid at Lys26 for albumin binding, achieving a ~7-day half-life through the peptide's own pharmacokinetic properties rather than a depot formulation. This approach avoids the immunogenicity issues associated with depot injection.
• vs. Liraglutide: Liraglutide uses a C16 fatty acid at Lys26 for albumin binding (half-life ~13 hours, daily dosing). No Aib substitution; uses Arg34Lys modification.
• vs. Albiglutide: Albiglutide achieves prolonged duration through genetic fusion of two GLP-1 copies to human albumin, creating a large (~73 kDa) fusion protein with ~5-day half-life.

Related Reading#

• Taspoglutide overview and research guide
• Peptides similar to Taspoglutide
• Taspoglutide research evidence